Last reviewed · How we verify
NCT03208764
Inhaled Nitric Oxide for Patients With MABSC
Phase 2 trial testing Nitric Oxide in Mycobacterium Abscessus Infection in 9 participants. Completed in 11 April 2019.
1 May 2018
Quick facts
| Lead sponsor | Beyond Air Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 24 July 2017 |
| Primary completion | 1 May 2018 |
| Estimated completion | 11 April 2019 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Nitric Oxide (NITRIC OXIDE) — full drug profile →
Conditions studied
- Mycobacterium Abscessus Infection — all drugs for Mycobacterium Abscessus Infection →
Sponsor
Beyond Air Inc. — full company profile →
Who can join
6 and older, any sex, with Mycobacterium Abscessus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Prospective, Open labeled, multi-Center, Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently via Inhalation to Subjects with NTM (specifically MABSC) Nitric Oxide (NO) has been shown to play a critical role in various biological functions. In the airways, NO is considered to play a key role in the innate immune system in which the first-line of host defense against microbes is built. In vitro studies suggested that NO, in part per million (ppm) concentrations, possesses anti-microbial activity against a wide variety of phyla including fungi, and antibiotic-resistance bacteria. In this study the investigators wish to evaluate the efficacy, safety and tolerability of 160 ppm Nitric Oxide intermittently delivered via inhalation to subjects infected with Non-tuberculosis mycobacteria (NTM), specifically with MABSC.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Inhaled Antibiotics for Mycobacterial Lung Disease.
Banaschewski B, Hofmann T. · · 2019 · cited 21× · PMID 31331119 · DOI 10.3390/pharmaceutics11070352 -
Toward better cures for <i>Mycobacterium abscessus</i> lung disease.
Dartois V, Dick T. · · 2024 · cited 10× · PMID 39360834 · DOI 10.1128/cmr.00080-23 -
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.
Gleeson LE, Waterer G. · · 2022 · cited 9× · PMID 36337137 · DOI 10.1183/20734735.0171-2021 -
Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer.
Tang Y, Li Q, Zhou Z, Bai H, et al · · 2024 · cited 8× · PMID 39497134 · DOI 10.1186/s12951-024-02929-z -
Nitric oxide-releasing prodrug for the treatment of complex <i>Mycobacterium abscessus</i> infections.
McDonald RA, Nagy SG, Chambers M, Broberg CA, et al · · 2024 · cited 8× · PMID 38206003 · DOI 10.1128/aac.01327-23 -
Clinical Trials involving <i>Mycobacterium abscessus</i>: An update.
Moore JE, Millar BC. · · 2025 · PMID 40313987
Verify or expand the search:
- PubMed search for NCT03208764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nitric Oxide
Trials testing the same drug.
- NCT05801224 — Vascular ARDS Recruitment After Inhaled Nitric Oxide · NA · suspended
- NCT06622291 — Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type A Aortic Dissection Patients · Phase 4 · completed
- NCT04181359 — The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. · Phase 1, PHASE2 · withdrawn
- NCT06120816 — Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis · Phase 1 · completed
- NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting
Other recruiting trials for Mycobacterium Abscessus Infection
Currently open trials in the same condition.
- NCT06004037 — Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex · Phase 2 · active not recruiting
Other Beyond Air Inc. trials
Trials by the same sponsor.
- NCT05351502 — A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors · Phase 1 · recruiting
- NCT04685720 — A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients · NA · completed
- NCT04606407 — Inhaled NO for the Treatment of Viral Pneumonia in Adults · NA · completed
- NCT04456088 — Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial) · Phase 2 · withdrawn
- NCT04397692 — Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03208764 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beyond Air Inc.
- Last refreshed: 9 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03208764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing